Advancements in artificial intelligence for meibography: clinical utility and contributions to meibomian gland dysfunction management.

Journal: Clinical & experimental optometry
Published Date:
(2)

Abstract

Recent advances in artificial intelligence (AI) have enhanced the capabilities of meibography by enabling objective and quantitative assessment of meibomian gland structure. This review explores the clinical utility of AI-based meibography in the diagnosis and management of Meibomian Gland Dysfunction (MGD), with a focus on segmentation, morphological analysis, and disease staging. Developments in deep learning have enabled more precise gland feature extraction, including gland dropout, density, and tortuosity, supporting efforts towards standardised and reproducible clinical evaluation. Although not the focus of this review, insights from traditional image processing techniques are referenced to highlight potential areas of improvement in current AI models. Key issues such as limited modelling of regional gland variation, restricted dataset diversity, and lack of standardised image quality control are discussed. Although significant progress has been made, further work is needed to ensure AI-driven meibography tools are generalisable, interpretable, and suitable for broad clinical implementation.

Authors

  • Kasandra Swiderska
    Division of Pharmacy and Optometry, The University of Manchester, Manchester, UK.
  • Caroline A Blackie
  • David Murakami
    Johnson & Johnson MedTech (Vision), Irvine, California.
  • Eugene Osae Appenteng
    Johnson & Johnson MedTech, Jacksonville, FL, USA.
  • Michael L Read
    Division of Pharmacy and Optometry, The University of Manchester, Manchester, UK.
  • Carole Maldonado-Codina
    Division of Pharmacy and Optometry, The University of Manchester, Manchester, UK.
  • Philip B Morgan
    Division of Pharmacy and Optometry, The University of Manchester, Manchester, UK.

Keywords

No keywords available for this article.